Enclomiphene has been studied for increasing endogenous testosterone, which can improve sperm production in some men with secondary hypogonadism. However, it is not an approved treatment for infertility, and its use should be limited to clinical trial settings or specialist supervision.
Enclomiphene is the trans-isomer of clomiphene, responsible for most of clomiphene’s estrogen-antagonist activity. It lacks the cis-isomer that contributes to clomiphene’s mixed agonist/antagonist effects, potentially offering a more predictable hormonal response.
Enclomiphene is a SERM and may be listed as a prohibited substance by certain sports governing bodies (e.g., WADA). Athletes should verify the specific regulations of their sport before using the medication.
Because Enclomiphene can interfere with estrogen signaling, it may reduce the effectiveness of estrogen-containing contraceptives. Alternative non-hormonal contraception should be considered.
Visual changes such as blurred vision or seeing spots are considered serious adverse events. Discontinue the medication and seek urgent medical evaluation.
In Hong Kong, compounding is limited to specific pharmacy settings. Any formulation changes must comply with local pharmacy regulations and be prescribed by a qualified clinician.
Food does not dramatically alter Enclomiphene absorption, but taking the pill consistently with or without meals helps maintain stable plasma concentrations.
St. John’s Wort, a CYP3A4 inducer, may lower Enclomiphene levels and reduce its effectiveness. Patients should discuss all herbal products with their healthcare provider.
Hormonal changes can be detected within a few days, but meaningful increases in serum testosterone generally become evident after 4-6 weeks of continuous therapy.
Since Enclomiphene is not an approved medication in Hong Kong, it is not listed on the public drug formulary and therefore not covered by government health insurance schemes.
Enclomiphene, whose active ingredient is Enclomiphene Citrate, belongs to the hormone therapy class of medications. It is supplied as a pill with a strength of 50 mg. In Hong Kong, Enclomiphene is not listed as an approved prescription drug by the Department of Health. Consequently, it is generally available only through clinical trial programs or specialist compounding, and specific manufacturer details are not publicly disclosed.
The medication is a selective estrogen receptor modulator (SERM) that influences the body’s hormonal signaling pathways. Although it is structurally related to the fertility drug clomiphene, Enclomiphene has been investigated primarily for its potential to raise testosterone levels in men with certain forms of hypogonadism.
Enclomiphene functions as a selective estrogen receptor modulator. By binding to estrogen receptors in the hypothalamus, it blocks the normal feedback inhibition that estrogen exerts on the brain. This blockade leads to:
The onset of hormonal changes typically occurs within a few days of the first dose, with peak effects observed after several weeks of consistent therapy. Enclomiphene is absorbed orally; its bioavailability is sufficient to achieve systemic levels that affect the hypothalamic-pituitary-gonadal axis.
As of the current regulatory status in Hong Kong, Enclomiphene does not have any FDA-equivalent approved indications. The medication is not authorized for routine prescription use for any condition.
In general, SERMs such as clomiphene are approved for female infertility and ovulation induction. Enclomiphene, being the trans-isomer of clomiphene, shares a similar pharmacologic profile but lacks formal approval for those indications.
Clinical studies have explored Enclomiphene as an oral option to raise endogenous testosterone in men with secondary (hypogonadotropic) hypogonadism. Research indicates that the drug can increase LH, FSH, and testosterone without the need for exogenous testosterone replacement.
No other off-label applications have sufficient peer-reviewed evidence to warrant inclusion.
If you fall into any of these categories, discuss alternative therapies with a qualified healthcare professional.
Patients should disclose all prescription drugs, over-the-counter products, herbal supplements, and dietary habits to their prescriber before starting Enclomiphene.
Because Enclomiphene is not an approved medication in Hong Kong, specific dosing tables are not provided. Always rely on professional medical advice for individualized regimens.
This article provides educational information about Enclomiphene and is not a substitute for professional medical advice. Treatment decisions, including the use of unapproved or off-label indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
